Atara Biotherapeutics

Update in progress

ATRA (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Atara Biotherapeutics develops transformative therapies for cancer and autoimmune diseases, in the U.S. and internationally. Its lead program, Tab-cel (tabelecleucel), is in Phase 3 for EBV-associated post-transplant lymphoproliferative disease and other EBV-driven conditions. It is also developing ATA3219, an allogeneic CD19 CAR-T for B-cell cancers and autoimmune diseases. Collaborations include MSK and QIMR. Founded in 2012, based in Thousand Oaks, CA.

Company score

Sentiment: -0.40; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.22; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.31; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.13; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.27; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive